Plaque Psoriasis
Study first to evaluate well-being as primary endpoint in patients with psoriasis
Almirall announced the publication of the first dermatological clinical study protocol to assess patient well-being as a primary endpoint in the treatment of moderate to severe plaque psoriasis, according to a company press release.
Tremfya outperforms IL-17 inhibitors in treatment persistence for plaque psoriasis
Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.
European Commission approves Sotyktu for adults with moderate to severe plaque psoriasis
The European Commission has approved Sotyktu in the European Union for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, Bristol Myers Squibb announced in a press release.
Topical therapies fall short of patient expectations during psoriasis treatment
Once-daily halobetasol propionate 0.01% and tazarotene 0.045% fixed-combination lotion stands out as a favorable treatment option amid topical therapies deemed unsatisfactory by psoriasis patients, according to a systematic review.
European Medicines Agency recommends Sotyktu for adults with plaque psoriasis
The European Medicines Agency has recommended the approval of Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.
CAL/BDP cream efficacious in plaque psoriasis treatment for patients with skin of color
WAILEA, Hawaii — A combination calcipotriene and betamethasone dipropionate cream showed similar efficacy in treating plaque psoriasis in patients with skin of color as it did in the full trial population, according to a post-hoc analysis.
Roflumilast-treated patients sustain psoriasis clearance for median 10 months
Once-daily Zoryve showed efficacy and an IGA of clear or almost clear for a median of 10 months in adults with chronic plaque psoriasis, Arcutis Biotherapeutics announced in a press release.
FDA accepts resubmitted biologics license application for bimekizumab for plaque psoriasis
The FDA has accepted the biologics license application resubmission for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis, according to a UCB release.
Arcutis submits supplemental NDA for Zoryve to treat plaque psoriasis in children
A supplemental new drug application has been submitted to the FDA for Zoryve cream for the treatment of plaque psoriasis in children aged 2 to 11 years, Arcutis Biotherapeutics announced in a press release.
Roflumilast cream significantly reduces itch in chronic plaque psoriasis
Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a once daily, topic treatment for chronic plaque psoriasis, according to a company press release.